nodes	percent_of_prediction	percent_of_DWPC	metapath
Prasugrel—CES2—Irinotecan—hematologic cancer	0.148	0.258	CbGbCtD
Prasugrel—ALB—hematologic cancer	0.12	1	CbGaD
Prasugrel—CYP2B6—Thiotepa—hematologic cancer	0.0291	0.0508	CbGbCtD
Prasugrel—CYP2C9—Bexarotene—hematologic cancer	0.0186	0.0324	CbGbCtD
Prasugrel—CYP2B6—Ifosfamide—hematologic cancer	0.0165	0.0288	CbGbCtD
Prasugrel—ALB—Imatinib—hematologic cancer	0.0155	0.027	CbGbCtD
Prasugrel—CYP2C9—Idarubicin—hematologic cancer	0.0154	0.0268	CbGbCtD
Prasugrel—CYP2B6—Nilotinib—hematologic cancer	0.0143	0.025	CbGbCtD
Prasugrel—CYP2C19—Bortezomib—hematologic cancer	0.0137	0.0239	CbGbCtD
Prasugrel—CYP2C19—Thalidomide—hematologic cancer	0.0119	0.0208	CbGbCtD
Prasugrel—CYP2C9—Bortezomib—hematologic cancer	0.0114	0.0198	CbGbCtD
Prasugrel—CYP2C19—Teniposide—hematologic cancer	0.0114	0.0198	CbGbCtD
Prasugrel—CYP3A4—Bexarotene—hematologic cancer	0.0108	0.0188	CbGbCtD
Prasugrel—CYP2C19—Ifosfamide—hematologic cancer	0.0105	0.0183	CbGbCtD
Prasugrel—ALB—Prednisone—hematologic cancer	0.0102	0.0178	CbGbCtD
Prasugrel—CYP3A4—Lomustine—hematologic cancer	0.01	0.0175	CbGbCtD
Prasugrel—CYP3A4—Busulfan—hematologic cancer	0.01	0.0175	CbGbCtD
Prasugrel—CYP2C19—Imatinib—hematologic cancer	0.01	0.0175	CbGbCtD
Prasugrel—CYP2C9—Thalidomide—hematologic cancer	0.00991	0.0173	CbGbCtD
Prasugrel—CYP2B6—Irinotecan—hematologic cancer	0.00985	0.0172	CbGbCtD
Prasugrel—ALB—Irinotecan—hematologic cancer	0.00966	0.0168	CbGbCtD
Prasugrel—CYP2C9—Teniposide—hematologic cancer	0.00945	0.0165	CbGbCtD
Prasugrel—CYP3A4—Thiotepa—hematologic cancer	0.00894	0.0156	CbGbCtD
Prasugrel—CYP2C9—Ifosfamide—hematologic cancer	0.00872	0.0152	CbGbCtD
Prasugrel—CYP2C9—Imatinib—hematologic cancer	0.00833	0.0145	CbGbCtD
Prasugrel—CYP2B6—Cisplatin—hematologic cancer	0.00803	0.014	CbGbCtD
Prasugrel—CYP2C9—Nilotinib—hematologic cancer	0.00757	0.0132	CbGbCtD
Prasugrel—CYP3A4—Methoxsalen—hematologic cancer	0.00695	0.0121	CbGbCtD
Prasugrel—CYP3A4—Bortezomib—hematologic cancer	0.00661	0.0115	CbGbCtD
Prasugrel—CYP2C19—Prednisone—hematologic cancer	0.00661	0.0115	CbGbCtD
Prasugrel—CYP2B6—Dexamethasone—hematologic cancer	0.00649	0.0113	CbGbCtD
Prasugrel—CYP3A4—Daunorubicin—hematologic cancer	0.00633	0.011	CbGbCtD
Prasugrel—CYP3A4—Cytarabine—hematologic cancer	0.00558	0.00973	CbGbCtD
Prasugrel—CYP3A4—Teniposide—hematologic cancer	0.0055	0.00959	CbGbCtD
Prasugrel—CYP2B6—Doxorubicin—hematologic cancer	0.00538	0.00939	CbGbCtD
Prasugrel—ALB—Methotrexate—hematologic cancer	0.00511	0.00891	CbGbCtD
Prasugrel—CYP3A4—Ifosfamide—hematologic cancer	0.00507	0.00885	CbGbCtD
Prasugrel—CYP3A4—Imatinib—hematologic cancer	0.00485	0.00845	CbGbCtD
Prasugrel—CYP3A4—Ruxolitinib—hematologic cancer	0.00456	0.00796	CbGbCtD
Prasugrel—CYP3A4—Nilotinib—hematologic cancer	0.0044	0.00768	CbGbCtD
Prasugrel—CYP3A4—Vinorelbine—hematologic cancer	0.00437	0.00762	CbGbCtD
Prasugrel—CYP2C9—Cisplatin—hematologic cancer	0.00424	0.0074	CbGbCtD
Prasugrel—CYP2C19—Dexamethasone—hematologic cancer	0.00412	0.00719	CbGbCtD
Prasugrel—CYP3A4—Triamcinolone—hematologic cancer	0.00399	0.00697	CbGbCtD
Prasugrel—CYP3A4—Dasatinib—hematologic cancer	0.00389	0.00679	CbGbCtD
Prasugrel—CYP3A4—Mitoxantrone—hematologic cancer	0.00384	0.00671	CbGbCtD
Prasugrel—P2RY12—hematopoietic system—hematologic cancer	0.00346	0.145	CbGeAlD
Prasugrel—CYP2C9—Dexamethasone—hematologic cancer	0.00343	0.00598	CbGbCtD
Prasugrel—CYP3A4—Betamethasone—hematologic cancer	0.00343	0.00598	CbGbCtD
Prasugrel—CYP3A4—Prednisolone—hematologic cancer	0.00338	0.0059	CbGbCtD
Prasugrel—CYP3A4—Prednisone—hematologic cancer	0.00319	0.00557	CbGbCtD
Prasugrel—CYP3A4—Irinotecan—hematologic cancer	0.00303	0.00528	CbGbCtD
Prasugrel—CYP3A4—Vinblastine—hematologic cancer	0.00269	0.00469	CbGbCtD
Prasugrel—CYP3A4—Vincristine—hematologic cancer	0.00265	0.00461	CbGbCtD
Prasugrel—CYP3A4—Etoposide—hematologic cancer	0.00242	0.00423	CbGbCtD
Prasugrel—P2RY12—blood—hematologic cancer	0.00229	0.0959	CbGeAlD
Prasugrel—CES2—hematopoietic system—hematologic cancer	0.0022	0.0923	CbGeAlD
Prasugrel—CYP3A4—Dexamethasone—hematologic cancer	0.00199	0.00348	CbGbCtD
Prasugrel—CES2—gonad—hematologic cancer	0.00168	0.0702	CbGeAlD
Prasugrel—CYP3A4—Doxorubicin—hematologic cancer	0.00165	0.00288	CbGbCtD
Prasugrel—CES2—blood—hematologic cancer	0.00146	0.0612	CbGeAlD
Prasugrel—CES2—bone marrow—hematologic cancer	0.00141	0.0592	CbGeAlD
Prasugrel—CES2—lung—hematologic cancer	0.00128	0.0536	CbGeAlD
Prasugrel—CES2—testis—hematologic cancer	0.00121	0.0506	CbGeAlD
Prasugrel—CYP2C19—hematopoietic system—hematologic cancer	0.00102	0.0425	CbGeAlD
Prasugrel—CES2—lymph node—hematologic cancer	0.000876	0.0367	CbGeAlD
Prasugrel—CYP2B6—hematopoietic system—hematologic cancer	0.000796	0.0333	CbGeAlD
Prasugrel—CYP2C9—hematopoietic system—hematologic cancer	0.000788	0.033	CbGeAlD
Prasugrel—ALB—testis—hematologic cancer	0.000692	0.029	CbGeAlD
Prasugrel—CYP2C19—blood—hematologic cancer	0.000673	0.0282	CbGeAlD
Prasugrel—CYP2B6—gonad—hematologic cancer	0.000605	0.0253	CbGeAlD
Prasugrel—CYP3A4—hematopoietic system—hematologic cancer	0.000601	0.0252	CbGeAlD
Prasugrel—CYP2B6—blood—hematologic cancer	0.000527	0.0221	CbGeAlD
Prasugrel—CYP2C9—blood—hematologic cancer	0.000522	0.0219	CbGeAlD
Prasugrel—ALB—lymph node—hematologic cancer	0.000501	0.021	CbGeAlD
Prasugrel—CYP2B6—lung—hematologic cancer	0.000462	0.0193	CbGeAlD
Prasugrel—CYP2B6—testis—hematologic cancer	0.000436	0.0183	CbGeAlD
Prasugrel—CYP3A4—blood—hematologic cancer	0.000398	0.0167	CbGeAlD
Prasugrel—Clopidogrel—ABCB1—hematologic cancer	0.000105	1	CrCbGaD
Prasugrel—Asthenia—Carmustine—hematologic cancer	5.89e-05	0.000282	CcSEcCtD
Prasugrel—Body temperature increased—Gemcitabine—hematologic cancer	5.88e-05	0.000281	CcSEcCtD
Prasugrel—Angioedema—Betamethasone—hematologic cancer	5.85e-05	0.00028	CcSEcCtD
Prasugrel—Angioedema—Dexamethasone—hematologic cancer	5.85e-05	0.00028	CcSEcCtD
Prasugrel—Diarrhoea—Thalidomide—hematologic cancer	5.85e-05	0.00028	CcSEcCtD
Prasugrel—Dizziness—Thiotepa—hematologic cancer	5.85e-05	0.00028	CcSEcCtD
Prasugrel—Asthenia—Alitretinoin—hematologic cancer	5.84e-05	0.000279	CcSEcCtD
Prasugrel—Rash—Vinorelbine—hematologic cancer	5.84e-05	0.000279	CcSEcCtD
Prasugrel—Dermatitis—Vinorelbine—hematologic cancer	5.83e-05	0.000279	CcSEcCtD
Prasugrel—Angiopathy—Prednisone—hematologic cancer	5.81e-05	0.000278	CcSEcCtD
Prasugrel—Headache—Vinorelbine—hematologic cancer	5.8e-05	0.000278	CcSEcCtD
Prasugrel—Immune system disorder—Prednisone—hematologic cancer	5.79e-05	0.000277	CcSEcCtD
Prasugrel—Hypersensitivity—Vincristine—hematologic cancer	5.78e-05	0.000276	CcSEcCtD
Prasugrel—Asthenia—Ifosfamide—hematologic cancer	5.77e-05	0.000276	CcSEcCtD
Prasugrel—Anaphylactic shock—Triamcinolone—hematologic cancer	5.76e-05	0.000276	CcSEcCtD
Prasugrel—Haematuria—Methotrexate—hematologic cancer	5.69e-05	0.000272	CcSEcCtD
Prasugrel—Dyspnoea—Etoposide—hematologic cancer	5.66e-05	0.000271	CcSEcCtD
Prasugrel—Dizziness—Thalidomide—hematologic cancer	5.65e-05	0.000271	CcSEcCtD
Prasugrel—Nausea—Bortezomib—hematologic cancer	5.63e-05	0.00027	CcSEcCtD
Prasugrel—Epistaxis—Methotrexate—hematologic cancer	5.63e-05	0.000269	CcSEcCtD
Prasugrel—Hypersensitivity—Irinotecan—hematologic cancer	5.63e-05	0.000269	CcSEcCtD
Prasugrel—Hypersensitivity—Mitoxantrone—hematologic cancer	5.63e-05	0.000269	CcSEcCtD
Prasugrel—Asthenia—Vincristine—hematologic cancer	5.63e-05	0.000269	CcSEcCtD
Prasugrel—Diarrhoea—Carmustine—hematologic cancer	5.62e-05	0.000269	CcSEcCtD
Prasugrel—Nausea—Bleomycin—hematologic cancer	5.59e-05	0.000267	CcSEcCtD
Prasugrel—Rash—Thiotepa—hematologic cancer	5.57e-05	0.000267	CcSEcCtD
Prasugrel—Dermatitis—Thiotepa—hematologic cancer	5.57e-05	0.000267	CcSEcCtD
Prasugrel—Diarrhoea—Alitretinoin—hematologic cancer	5.57e-05	0.000266	CcSEcCtD
Prasugrel—Headache—Thiotepa—hematologic cancer	5.54e-05	0.000265	CcSEcCtD
Prasugrel—Hypertension—Dexamethasone—hematologic cancer	5.53e-05	0.000265	CcSEcCtD
Prasugrel—Hypertension—Betamethasone—hematologic cancer	5.53e-05	0.000265	CcSEcCtD
Prasugrel—Diarrhoea—Ifosfamide—hematologic cancer	5.5e-05	0.000263	CcSEcCtD
Prasugrel—Nausea—Vinorelbine—hematologic cancer	5.5e-05	0.000263	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Etoposide—hematologic cancer	5.48e-05	0.000262	CcSEcCtD
Prasugrel—Body temperature increased—Cisplatin—hematologic cancer	5.48e-05	0.000262	CcSEcCtD
Prasugrel—Asthenia—Mitoxantrone—hematologic cancer	5.48e-05	0.000262	CcSEcCtD
Prasugrel—Asthenia—Irinotecan—hematologic cancer	5.48e-05	0.000262	CcSEcCtD
Prasugrel—Fatigue—Etoposide—hematologic cancer	5.48e-05	0.000262	CcSEcCtD
Prasugrel—Dizziness—Carmustine—hematologic cancer	5.43e-05	0.00026	CcSEcCtD
Prasugrel—Rash—Thalidomide—hematologic cancer	5.39e-05	0.000258	CcSEcCtD
Prasugrel—Dermatitis—Thalidomide—hematologic cancer	5.39e-05	0.000258	CcSEcCtD
Prasugrel—Haemoglobin—Methotrexate—hematologic cancer	5.38e-05	0.000258	CcSEcCtD
Prasugrel—Dizziness—Alitretinoin—hematologic cancer	5.38e-05	0.000258	CcSEcCtD
Prasugrel—Diarrhoea—Vincristine—hematologic cancer	5.36e-05	0.000257	CcSEcCtD
Prasugrel—Headache—Thalidomide—hematologic cancer	5.36e-05	0.000256	CcSEcCtD
Prasugrel—Haemorrhage—Methotrexate—hematologic cancer	5.35e-05	0.000256	CcSEcCtD
Prasugrel—Asthenia—Gemcitabine—hematologic cancer	5.34e-05	0.000255	CcSEcCtD
Prasugrel—Haematuria—Epirubicin—hematologic cancer	5.32e-05	0.000255	CcSEcCtD
Prasugrel—Dizziness—Ifosfamide—hematologic cancer	5.32e-05	0.000255	CcSEcCtD
Prasugrel—Urinary tract disorder—Methotrexate—hematologic cancer	5.29e-05	0.000253	CcSEcCtD
Prasugrel—Epistaxis—Epirubicin—hematologic cancer	5.26e-05	0.000252	CcSEcCtD
Prasugrel—Nausea—Thiotepa—hematologic cancer	5.25e-05	0.000251	CcSEcCtD
Prasugrel—Urethral disorder—Methotrexate—hematologic cancer	5.25e-05	0.000251	CcSEcCtD
Prasugrel—Anaphylactic shock—Betamethasone—hematologic cancer	5.23e-05	0.00025	CcSEcCtD
Prasugrel—Anaphylactic shock—Dexamethasone—hematologic cancer	5.23e-05	0.00025	CcSEcCtD
Prasugrel—Diarrhoea—Irinotecan—hematologic cancer	5.22e-05	0.00025	CcSEcCtD
Prasugrel—Diarrhoea—Mitoxantrone—hematologic cancer	5.22e-05	0.00025	CcSEcCtD
Prasugrel—Dizziness—Vincristine—hematologic cancer	5.18e-05	0.000248	CcSEcCtD
Prasugrel—Rash—Carmustine—hematologic cancer	5.18e-05	0.000248	CcSEcCtD
Prasugrel—Dermatitis—Carmustine—hematologic cancer	5.17e-05	0.000248	CcSEcCtD
Prasugrel—Anaemia—Prednisone—hematologic cancer	5.16e-05	0.000247	CcSEcCtD
Prasugrel—Headache—Carmustine—hematologic cancer	5.15e-05	0.000246	CcSEcCtD
Prasugrel—Dyspnoea—Triamcinolone—hematologic cancer	5.14e-05	0.000246	CcSEcCtD
Prasugrel—Rash—Alitretinoin—hematologic cancer	5.13e-05	0.000246	CcSEcCtD
Prasugrel—Dermatitis—Alitretinoin—hematologic cancer	5.13e-05	0.000245	CcSEcCtD
Prasugrel—Thrombocytopenia—Dexamethasone—hematologic cancer	5.12e-05	0.000245	CcSEcCtD
Prasugrel—Thrombocytopenia—Betamethasone—hematologic cancer	5.12e-05	0.000245	CcSEcCtD
Prasugrel—Hypersensitivity—Cisplatin—hematologic cancer	5.11e-05	0.000244	CcSEcCtD
Prasugrel—Bradycardia—Epirubicin—hematologic cancer	5.1e-05	0.000244	CcSEcCtD
Prasugrel—Headache—Alitretinoin—hematologic cancer	5.1e-05	0.000244	CcSEcCtD
Prasugrel—Angioedema—Prednisone—hematologic cancer	5.1e-05	0.000244	CcSEcCtD
Prasugrel—Diarrhoea—Gemcitabine—hematologic cancer	5.09e-05	0.000244	CcSEcCtD
Prasugrel—Nausea—Thalidomide—hematologic cancer	5.08e-05	0.000243	CcSEcCtD
Prasugrel—Rash—Ifosfamide—hematologic cancer	5.07e-05	0.000243	CcSEcCtD
Prasugrel—Dermatitis—Ifosfamide—hematologic cancer	5.07e-05	0.000242	CcSEcCtD
Prasugrel—Dizziness—Irinotecan—hematologic cancer	5.05e-05	0.000242	CcSEcCtD
Prasugrel—Haemoglobin—Epirubicin—hematologic cancer	5.04e-05	0.000241	CcSEcCtD
Prasugrel—Body temperature increased—Etoposide—hematologic cancer	5.02e-05	0.00024	CcSEcCtD
Prasugrel—Haemorrhage—Epirubicin—hematologic cancer	5.01e-05	0.00024	CcSEcCtD
Prasugrel—Eye disorder—Methotrexate—hematologic cancer	5e-05	0.00024	CcSEcCtD
Prasugrel—Asthenia—Cisplatin—hematologic cancer	4.97e-05	0.000238	CcSEcCtD
Prasugrel—Fatigue—Triamcinolone—hematologic cancer	4.97e-05	0.000238	CcSEcCtD
Prasugrel—Urinary tract disorder—Epirubicin—hematologic cancer	4.95e-05	0.000237	CcSEcCtD
Prasugrel—Rash—Vincristine—hematologic cancer	4.94e-05	0.000237	CcSEcCtD
Prasugrel—Dermatitis—Vincristine—hematologic cancer	4.94e-05	0.000236	CcSEcCtD
Prasugrel—Oedema peripheral—Epirubicin—hematologic cancer	4.94e-05	0.000236	CcSEcCtD
Prasugrel—Haematuria—Doxorubicin—hematologic cancer	4.92e-05	0.000236	CcSEcCtD
Prasugrel—Urethral disorder—Epirubicin—hematologic cancer	4.91e-05	0.000235	CcSEcCtD
Prasugrel—Headache—Vincristine—hematologic cancer	4.91e-05	0.000235	CcSEcCtD
Prasugrel—Hypotension—Betamethasone—hematologic cancer	4.88e-05	0.000234	CcSEcCtD
Prasugrel—Hypotension—Dexamethasone—hematologic cancer	4.88e-05	0.000234	CcSEcCtD
Prasugrel—Nausea—Carmustine—hematologic cancer	4.88e-05	0.000233	CcSEcCtD
Prasugrel—Epistaxis—Doxorubicin—hematologic cancer	4.87e-05	0.000233	CcSEcCtD
Prasugrel—Angiopathy—Methotrexate—hematologic cancer	4.86e-05	0.000233	CcSEcCtD
Prasugrel—Immune system disorder—Methotrexate—hematologic cancer	4.84e-05	0.000231	CcSEcCtD
Prasugrel—Nausea—Alitretinoin—hematologic cancer	4.83e-05	0.000231	CcSEcCtD
Prasugrel—Mediastinal disorder—Methotrexate—hematologic cancer	4.83e-05	0.000231	CcSEcCtD
Prasugrel—Hypertension—Prednisone—hematologic cancer	4.82e-05	0.00023	CcSEcCtD
Prasugrel—Rash—Irinotecan—hematologic cancer	4.81e-05	0.00023	CcSEcCtD
Prasugrel—Rash—Mitoxantrone—hematologic cancer	4.81e-05	0.00023	CcSEcCtD
Prasugrel—Dermatitis—Mitoxantrone—hematologic cancer	4.81e-05	0.00023	CcSEcCtD
Prasugrel—Dermatitis—Irinotecan—hematologic cancer	4.81e-05	0.00023	CcSEcCtD
Prasugrel—Headache—Irinotecan—hematologic cancer	4.78e-05	0.000229	CcSEcCtD
Prasugrel—Headache—Mitoxantrone—hematologic cancer	4.78e-05	0.000229	CcSEcCtD
Prasugrel—Nausea—Ifosfamide—hematologic cancer	4.78e-05	0.000229	CcSEcCtD
Prasugrel—Diarrhoea—Cisplatin—hematologic cancer	4.74e-05	0.000227	CcSEcCtD
Prasugrel—Bradycardia—Doxorubicin—hematologic cancer	4.72e-05	0.000226	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.72e-05	0.000226	CcSEcCtD
Prasugrel—Rash—Gemcitabine—hematologic cancer	4.69e-05	0.000224	CcSEcCtD
Prasugrel—Dermatitis—Gemcitabine—hematologic cancer	4.69e-05	0.000224	CcSEcCtD
Prasugrel—Eye disorder—Epirubicin—hematologic cancer	4.68e-05	0.000224	CcSEcCtD
Prasugrel—Hypersensitivity—Etoposide—hematologic cancer	4.68e-05	0.000224	CcSEcCtD
Prasugrel—Haemoglobin—Doxorubicin—hematologic cancer	4.66e-05	0.000223	CcSEcCtD
Prasugrel—Headache—Gemcitabine—hematologic cancer	4.66e-05	0.000223	CcSEcCtD
Prasugrel—Nausea—Vincristine—hematologic cancer	4.66e-05	0.000223	CcSEcCtD
Prasugrel—Haemorrhage—Doxorubicin—hematologic cancer	4.64e-05	0.000222	CcSEcCtD
Prasugrel—Hypersensitivity—Prednisolone—hematologic cancer	4.62e-05	0.000221	CcSEcCtD
Prasugrel—Urinary tract disorder—Doxorubicin—hematologic cancer	4.58e-05	0.000219	CcSEcCtD
Prasugrel—Oedema peripheral—Doxorubicin—hematologic cancer	4.57e-05	0.000219	CcSEcCtD
Prasugrel—Asthenia—Etoposide—hematologic cancer	4.56e-05	0.000218	CcSEcCtD
Prasugrel—Body temperature increased—Triamcinolone—hematologic cancer	4.55e-05	0.000218	CcSEcCtD
Prasugrel—Anaphylactic shock—Prednisone—hematologic cancer	4.55e-05	0.000218	CcSEcCtD
Prasugrel—Angiopathy—Epirubicin—hematologic cancer	4.55e-05	0.000218	CcSEcCtD
Prasugrel—Urethral disorder—Doxorubicin—hematologic cancer	4.55e-05	0.000218	CcSEcCtD
Prasugrel—Nausea—Mitoxantrone—hematologic cancer	4.54e-05	0.000217	CcSEcCtD
Prasugrel—Nausea—Irinotecan—hematologic cancer	4.54e-05	0.000217	CcSEcCtD
Prasugrel—Immune system disorder—Epirubicin—hematologic cancer	4.53e-05	0.000217	CcSEcCtD
Prasugrel—Mediastinal disorder—Epirubicin—hematologic cancer	4.52e-05	0.000216	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.51e-05	0.000216	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.51e-05	0.000216	CcSEcCtD
Prasugrel—Back pain—Methotrexate—hematologic cancer	4.51e-05	0.000216	CcSEcCtD
Prasugrel—Fatigue—Betamethasone—hematologic cancer	4.51e-05	0.000216	CcSEcCtD
Prasugrel—Fatigue—Dexamethasone—hematologic cancer	4.51e-05	0.000216	CcSEcCtD
Prasugrel—Skin disorder—Prednisone—hematologic cancer	4.42e-05	0.000212	CcSEcCtD
Prasugrel—Nausea—Gemcitabine—hematologic cancer	4.42e-05	0.000211	CcSEcCtD
Prasugrel—Rash—Cisplatin—hematologic cancer	4.37e-05	0.000209	CcSEcCtD
Prasugrel—Dermatitis—Cisplatin—hematologic cancer	4.37e-05	0.000209	CcSEcCtD
Prasugrel—Diarrhoea—Etoposide—hematologic cancer	4.35e-05	0.000208	CcSEcCtD
Prasugrel—Eye disorder—Doxorubicin—hematologic cancer	4.33e-05	0.000207	CcSEcCtD
Prasugrel—Anaemia—Methotrexate—hematologic cancer	4.31e-05	0.000206	CcSEcCtD
Prasugrel—Hypersensitivity—Triamcinolone—hematologic cancer	4.24e-05	0.000203	CcSEcCtD
Prasugrel—Back pain—Epirubicin—hematologic cancer	4.22e-05	0.000202	CcSEcCtD
Prasugrel—Angiopathy—Doxorubicin—hematologic cancer	4.21e-05	0.000201	CcSEcCtD
Prasugrel—Dizziness—Etoposide—hematologic cancer	4.2e-05	0.000201	CcSEcCtD
Prasugrel—Immune system disorder—Doxorubicin—hematologic cancer	4.19e-05	0.0002	CcSEcCtD
Prasugrel—Mediastinal disorder—Doxorubicin—hematologic cancer	4.18e-05	0.0002	CcSEcCtD
Prasugrel—Leukopenia—Methotrexate—hematologic cancer	4.17e-05	0.0002	CcSEcCtD
Prasugrel—Dizziness—Prednisolone—hematologic cancer	4.14e-05	0.000198	CcSEcCtD
Prasugrel—Asthenia—Triamcinolone—hematologic cancer	4.13e-05	0.000198	CcSEcCtD
Prasugrel—Body temperature increased—Betamethasone—hematologic cancer	4.13e-05	0.000198	CcSEcCtD
Prasugrel—Body temperature increased—Dexamethasone—hematologic cancer	4.13e-05	0.000198	CcSEcCtD
Prasugrel—Nausea—Cisplatin—hematologic cancer	4.12e-05	0.000197	CcSEcCtD
Prasugrel—Cough—Methotrexate—hematologic cancer	4.07e-05	0.000195	CcSEcCtD
Prasugrel—Anaemia—Epirubicin—hematologic cancer	4.03e-05	0.000193	CcSEcCtD
Prasugrel—Rash—Etoposide—hematologic cancer	4e-05	0.000192	CcSEcCtD
Prasugrel—Dermatitis—Etoposide—hematologic cancer	4e-05	0.000191	CcSEcCtD
Prasugrel—Headache—Etoposide—hematologic cancer	3.98e-05	0.00019	CcSEcCtD
Prasugrel—Rash—Prednisolone—hematologic cancer	3.95e-05	0.000189	CcSEcCtD
Prasugrel—Dermatitis—Prednisolone—hematologic cancer	3.95e-05	0.000189	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.94e-05	0.000189	CcSEcCtD
Prasugrel—Fatigue—Prednisone—hematologic cancer	3.92e-05	0.000188	CcSEcCtD
Prasugrel—Headache—Prednisolone—hematologic cancer	3.92e-05	0.000188	CcSEcCtD
Prasugrel—Leukopenia—Epirubicin—hematologic cancer	3.9e-05	0.000187	CcSEcCtD
Prasugrel—Back pain—Doxorubicin—hematologic cancer	3.9e-05	0.000187	CcSEcCtD
Prasugrel—Dizziness—Triamcinolone—hematologic cancer	3.81e-05	0.000182	CcSEcCtD
Prasugrel—Cough—Epirubicin—hematologic cancer	3.81e-05	0.000182	CcSEcCtD
Prasugrel—Anaphylactic shock—Methotrexate—hematologic cancer	3.8e-05	0.000182	CcSEcCtD
Prasugrel—Nausea—Etoposide—hematologic cancer	3.77e-05	0.000181	CcSEcCtD
Prasugrel—Hypertension—Epirubicin—hematologic cancer	3.77e-05	0.00018	CcSEcCtD
Prasugrel—Asthenia—Betamethasone—hematologic cancer	3.75e-05	0.000179	CcSEcCtD
Prasugrel—Asthenia—Dexamethasone—hematologic cancer	3.75e-05	0.000179	CcSEcCtD
Prasugrel—Anaemia—Doxorubicin—hematologic cancer	3.73e-05	0.000179	CcSEcCtD
Prasugrel—Thrombocytopenia—Methotrexate—hematologic cancer	3.72e-05	0.000178	CcSEcCtD
Prasugrel—Nausea—Prednisolone—hematologic cancer	3.72e-05	0.000178	CcSEcCtD
Prasugrel—Skin disorder—Methotrexate—hematologic cancer	3.7e-05	0.000177	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.69e-05	0.000177	CcSEcCtD
Prasugrel—Rash—Triamcinolone—hematologic cancer	3.63e-05	0.000174	CcSEcCtD
Prasugrel—Dermatitis—Triamcinolone—hematologic cancer	3.63e-05	0.000174	CcSEcCtD
Prasugrel—Leukopenia—Doxorubicin—hematologic cancer	3.61e-05	0.000173	CcSEcCtD
Prasugrel—Headache—Triamcinolone—hematologic cancer	3.61e-05	0.000173	CcSEcCtD
Prasugrel—Body temperature increased—Prednisone—hematologic cancer	3.6e-05	0.000172	CcSEcCtD
Prasugrel—Diarrhoea—Dexamethasone—hematologic cancer	3.58e-05	0.000171	CcSEcCtD
Prasugrel—Diarrhoea—Betamethasone—hematologic cancer	3.58e-05	0.000171	CcSEcCtD
Prasugrel—Anaphylactic shock—Epirubicin—hematologic cancer	3.56e-05	0.00017	CcSEcCtD
Prasugrel—Hypotension—Methotrexate—hematologic cancer	3.55e-05	0.00017	CcSEcCtD
Prasugrel—Cough—Doxorubicin—hematologic cancer	3.52e-05	0.000169	CcSEcCtD
Prasugrel—Thrombocytopenia—Epirubicin—hematologic cancer	3.49e-05	0.000167	CcSEcCtD
Prasugrel—Hypertension—Doxorubicin—hematologic cancer	3.48e-05	0.000167	CcSEcCtD
Prasugrel—Skin disorder—Epirubicin—hematologic cancer	3.46e-05	0.000166	CcSEcCtD
Prasugrel—Dizziness—Dexamethasone—hematologic cancer	3.46e-05	0.000165	CcSEcCtD
Prasugrel—Dizziness—Betamethasone—hematologic cancer	3.46e-05	0.000165	CcSEcCtD
Prasugrel—Nausea—Triamcinolone—hematologic cancer	3.42e-05	0.000164	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.41e-05	0.000163	CcSEcCtD
Prasugrel—Dyspnoea—Methotrexate—hematologic cancer	3.39e-05	0.000162	CcSEcCtD
Prasugrel—Hypersensitivity—Prednisone—hematologic cancer	3.35e-05	0.000161	CcSEcCtD
Prasugrel—Hypotension—Epirubicin—hematologic cancer	3.33e-05	0.000159	CcSEcCtD
Prasugrel—Rash—Betamethasone—hematologic cancer	3.3e-05	0.000158	CcSEcCtD
Prasugrel—Rash—Dexamethasone—hematologic cancer	3.3e-05	0.000158	CcSEcCtD
Prasugrel—Anaphylactic shock—Doxorubicin—hematologic cancer	3.29e-05	0.000158	CcSEcCtD
Prasugrel—Dermatitis—Dexamethasone—hematologic cancer	3.29e-05	0.000158	CcSEcCtD
Prasugrel—Dermatitis—Betamethasone—hematologic cancer	3.29e-05	0.000158	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.28e-05	0.000157	CcSEcCtD
Prasugrel—Fatigue—Methotrexate—hematologic cancer	3.28e-05	0.000157	CcSEcCtD
Prasugrel—Headache—Dexamethasone—hematologic cancer	3.27e-05	0.000157	CcSEcCtD
Prasugrel—Headache—Betamethasone—hematologic cancer	3.27e-05	0.000157	CcSEcCtD
Prasugrel—Asthenia—Prednisone—hematologic cancer	3.27e-05	0.000156	CcSEcCtD
Prasugrel—Thrombocytopenia—Doxorubicin—hematologic cancer	3.23e-05	0.000154	CcSEcCtD
Prasugrel—Skin disorder—Doxorubicin—hematologic cancer	3.2e-05	0.000153	CcSEcCtD
Prasugrel—Dyspnoea—Epirubicin—hematologic cancer	3.17e-05	0.000152	CcSEcCtD
Prasugrel—Diarrhoea—Prednisone—hematologic cancer	3.11e-05	0.000149	CcSEcCtD
Prasugrel—Nausea—Dexamethasone—hematologic cancer	3.1e-05	0.000149	CcSEcCtD
Prasugrel—Nausea—Betamethasone—hematologic cancer	3.1e-05	0.000149	CcSEcCtD
Prasugrel—Hypotension—Doxorubicin—hematologic cancer	3.08e-05	0.000147	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.07e-05	0.000147	CcSEcCtD
Prasugrel—Fatigue—Epirubicin—hematologic cancer	3.07e-05	0.000147	CcSEcCtD
Prasugrel—Dizziness—Prednisone—hematologic cancer	3.01e-05	0.000144	CcSEcCtD
Prasugrel—Body temperature increased—Methotrexate—hematologic cancer	3.01e-05	0.000144	CcSEcCtD
Prasugrel—Dyspnoea—Doxorubicin—hematologic cancer	2.94e-05	0.000141	CcSEcCtD
Prasugrel—Rash—Prednisone—hematologic cancer	2.87e-05	0.000137	CcSEcCtD
Prasugrel—Dermatitis—Prednisone—hematologic cancer	2.87e-05	0.000137	CcSEcCtD
Prasugrel—Headache—Prednisone—hematologic cancer	2.85e-05	0.000136	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.84e-05	0.000136	CcSEcCtD
Prasugrel—Fatigue—Doxorubicin—hematologic cancer	2.84e-05	0.000136	CcSEcCtD
Prasugrel—Body temperature increased—Epirubicin—hematologic cancer	2.81e-05	0.000135	CcSEcCtD
Prasugrel—Hypersensitivity—Methotrexate—hematologic cancer	2.8e-05	0.000134	CcSEcCtD
Prasugrel—Asthenia—Methotrexate—hematologic cancer	2.73e-05	0.000131	CcSEcCtD
Prasugrel—Nausea—Prednisone—hematologic cancer	2.7e-05	0.000129	CcSEcCtD
Prasugrel—Hypersensitivity—Epirubicin—hematologic cancer	2.62e-05	0.000126	CcSEcCtD
Prasugrel—Body temperature increased—Doxorubicin—hematologic cancer	2.6e-05	0.000125	CcSEcCtD
Prasugrel—Diarrhoea—Methotrexate—hematologic cancer	2.6e-05	0.000125	CcSEcCtD
Prasugrel—Asthenia—Epirubicin—hematologic cancer	2.55e-05	0.000122	CcSEcCtD
Prasugrel—Dizziness—Methotrexate—hematologic cancer	2.52e-05	0.00012	CcSEcCtD
Prasugrel—Diarrhoea—Epirubicin—hematologic cancer	2.44e-05	0.000117	CcSEcCtD
Prasugrel—Hypersensitivity—Doxorubicin—hematologic cancer	2.43e-05	0.000116	CcSEcCtD
Prasugrel—Rash—Methotrexate—hematologic cancer	2.4e-05	0.000115	CcSEcCtD
Prasugrel—Dermatitis—Methotrexate—hematologic cancer	2.4e-05	0.000115	CcSEcCtD
Prasugrel—Headache—Methotrexate—hematologic cancer	2.38e-05	0.000114	CcSEcCtD
Prasugrel—Asthenia—Doxorubicin—hematologic cancer	2.36e-05	0.000113	CcSEcCtD
Prasugrel—Dizziness—Epirubicin—hematologic cancer	2.35e-05	0.000113	CcSEcCtD
Prasugrel—Nausea—Methotrexate—hematologic cancer	2.26e-05	0.000108	CcSEcCtD
Prasugrel—Diarrhoea—Doxorubicin—hematologic cancer	2.25e-05	0.000108	CcSEcCtD
Prasugrel—Rash—Epirubicin—hematologic cancer	2.24e-05	0.000107	CcSEcCtD
Prasugrel—Dermatitis—Epirubicin—hematologic cancer	2.24e-05	0.000107	CcSEcCtD
Prasugrel—Headache—Epirubicin—hematologic cancer	2.23e-05	0.000107	CcSEcCtD
Prasugrel—Dizziness—Doxorubicin—hematologic cancer	2.18e-05	0.000104	CcSEcCtD
Prasugrel—Nausea—Epirubicin—hematologic cancer	2.11e-05	0.000101	CcSEcCtD
Prasugrel—Rash—Doxorubicin—hematologic cancer	2.08e-05	9.94e-05	CcSEcCtD
Prasugrel—Dermatitis—Doxorubicin—hematologic cancer	2.08e-05	9.93e-05	CcSEcCtD
Prasugrel—Headache—Doxorubicin—hematologic cancer	2.06e-05	9.88e-05	CcSEcCtD
Prasugrel—Nausea—Doxorubicin—hematologic cancer	1.96e-05	9.36e-05	CcSEcCtD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	8.36e-06	0.000114	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ARNTL—hematologic cancer	8.34e-06	0.000113	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CG—hematologic cancer	8.33e-06	0.000113	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—HRAS—hematologic cancer	8.32e-06	0.000113	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CDA—hematologic cancer	8.3e-06	0.000113	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—SDC1—hematologic cancer	8.29e-06	0.000113	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ABCC3—hematologic cancer	8.27e-06	0.000112	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—TXN—hematologic cancer	8.27e-06	0.000112	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTO1—hematologic cancer	8.27e-06	0.000112	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ALOX5—hematologic cancer	8.21e-06	0.000111	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PTPN11—hematologic cancer	8.18e-06	0.000111	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDKN1B—hematologic cancer	8.18e-06	0.000111	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ACP5—hematologic cancer	8.11e-06	0.00011	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CA9—hematologic cancer	8.11e-06	0.00011	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—AKT1—hematologic cancer	8.09e-06	0.00011	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SPHK1—hematologic cancer	8.09e-06	0.00011	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CASP3—hematologic cancer	8.02e-06	0.000109	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL2—hematologic cancer	8.01e-06	0.000109	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NCOR2—hematologic cancer	8e-06	0.000109	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PC—hematologic cancer	7.99e-06	0.000108	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—IL6—hematologic cancer	7.97e-06	0.000108	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NUP98—hematologic cancer	7.95e-06	0.000108	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CCND1—hematologic cancer	7.81e-06	0.000106	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—JUN—hematologic cancer	7.79e-06	0.000106	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—UGT1A1—hematologic cancer	7.77e-06	0.000106	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—CREBBP—hematologic cancer	7.72e-06	0.000105	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ADCY7—hematologic cancer	7.72e-06	0.000105	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NCOA3—hematologic cancer	7.72e-06	0.000105	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GBA—hematologic cancer	7.72e-06	0.000105	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SLC35B2—hematologic cancer	7.72e-06	0.000105	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NUP214—hematologic cancer	7.66e-06	0.000104	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—IDH1—hematologic cancer	7.62e-06	0.000104	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.58e-06	0.000103	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CRABP1—hematologic cancer	7.56e-06	0.000103	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SLC22A1—hematologic cancer	7.56e-06	0.000103	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDKN1A—hematologic cancer	7.55e-06	0.000103	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	7.55e-06	0.000103	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTO1—hematologic cancer	7.54e-06	0.000102	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ABCC3—hematologic cancer	7.54e-06	0.000102	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—TXN—hematologic cancer	7.54e-06	0.000102	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PTEN—hematologic cancer	7.53e-06	0.000102	CbGpPWpGaD
Prasugrel—ALB—Metabolism—MTR—hematologic cancer	7.51e-06	0.000102	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ABCG2—hematologic cancer	7.51e-06	0.000102	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SPHK1—hematologic cancer	7.38e-06	0.0001	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MAPK8—hematologic cancer	7.37e-06	0.0001	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ALOX5—hematologic cancer	7.37e-06	0.0001	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ENO2—hematologic cancer	7.36e-06	0.0001	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—AKT1—hematologic cancer	7.35e-06	9.98e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CD—hematologic cancer	7.32e-06	9.95e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EP300—hematologic cancer	7.18e-06	9.76e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTT1—hematologic cancer	7.14e-06	9.7e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NUP98—hematologic cancer	7.14e-06	9.69e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—UGT1A1—hematologic cancer	7.09e-06	9.63e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—MTAP—hematologic cancer	7.06e-06	9.58e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NQO1—hematologic cancer	7.05e-06	9.58e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CD44—hematologic cancer	7.05e-06	9.58e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.03e-06	9.55e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SRC—hematologic cancer	6.99e-06	9.49e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—SDC1—hematologic cancer	6.98e-06	9.48e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ADCY7—hematologic cancer	6.93e-06	9.41e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NCOA3—hematologic cancer	6.93e-06	9.41e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3R1—hematologic cancer	6.92e-06	9.39e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CRABP1—hematologic cancer	6.89e-06	9.36e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SLC22A1—hematologic cancer	6.89e-06	9.36e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NUP214—hematologic cancer	6.88e-06	9.34e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.81e-06	9.25e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—VEGFA—hematologic cancer	6.8e-06	9.24e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—MTR—hematologic cancer	6.74e-06	9.15e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ABCG2—hematologic cancer	6.74e-06	9.15e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—STAT3—hematologic cancer	6.74e-06	9.15e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—NRAS—hematologic cancer	6.72e-06	9.13e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—JAK2—hematologic cancer	6.72e-06	9.13e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ALOX5—hematologic cancer	6.72e-06	9.13e-05	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	6.69e-06	9.08e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYCS—hematologic cancer	6.67e-06	9.06e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.67e-06	9.06e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—HSP90AA1—hematologic cancer	6.63e-06	9e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ENO2—hematologic cancer	6.61e-06	8.98e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NUP98—hematologic cancer	6.51e-06	8.84e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MAPK3—hematologic cancer	6.44e-06	8.74e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTT1—hematologic cancer	6.41e-06	8.71e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CB—hematologic cancer	6.38e-06	8.67e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ADCY7—hematologic cancer	6.32e-06	8.58e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NCOA3—hematologic cancer	6.32e-06	8.58e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.31e-06	8.57e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.3e-06	8.55e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—FHL2—hematologic cancer	6.29e-06	8.54e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NUP214—hematologic cancer	6.27e-06	8.52e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SDC1—hematologic cancer	6.27e-06	8.51e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MYC—hematologic cancer	6.26e-06	8.5e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TGFB1—hematologic cancer	6.25e-06	8.48e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.21e-06	8.43e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AGRN—hematologic cancer	6.17e-06	8.38e-05	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	6.17e-06	8.38e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ABCG2—hematologic cancer	6.15e-06	8.35e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—MTR—hematologic cancer	6.15e-06	8.35e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ENO2—hematologic cancer	6.03e-06	8.18e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.98e-06	8.13e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NQO1—hematologic cancer	5.93e-06	8.06e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CD44—hematologic cancer	5.93e-06	8.06e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.91e-06	8.02e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTP1—hematologic cancer	5.88e-06	7.99e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IL2—hematologic cancer	5.86e-06	7.96e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—IDH2—hematologic cancer	5.85e-06	7.94e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—HMMR—hematologic cancer	5.85e-06	7.94e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTT1—hematologic cancer	5.85e-06	7.94e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.81e-06	7.89e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—KRAS—hematologic cancer	5.78e-06	7.86e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	5.76e-06	7.82e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SDC1—hematologic cancer	5.71e-06	7.76e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.65e-06	7.68e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYCS—hematologic cancer	5.62e-06	7.63e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—HSP90AA1—hematologic cancer	5.58e-06	7.58e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—ABCB1—hematologic cancer	5.57e-06	7.56e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ARNTL—hematologic cancer	5.5e-06	7.47e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.46e-06	7.41e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTM1—hematologic cancer	5.4e-06	7.34e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NCOR1—hematologic cancer	5.4e-06	7.34e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.39e-06	7.32e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CA9—hematologic cancer	5.35e-06	7.26e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ACP5—hematologic cancer	5.35e-06	7.26e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CD44—hematologic cancer	5.33e-06	7.24e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NQO1—hematologic cancer	5.33e-06	7.24e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PIK3CA—hematologic cancer	5.31e-06	7.22e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NCOR2—hematologic cancer	5.28e-06	7.17e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—EP300—hematologic cancer	5.26e-06	7.14e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.22e-06	7.09e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.15e-06	7e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TP53—hematologic cancer	5.14e-06	6.98e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—SRC—hematologic cancer	5.12e-06	6.95e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYCS—hematologic cancer	5.04e-06	6.85e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—IDH1—hematologic cancer	5.03e-06	6.83e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.02e-06	6.82e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	5.01e-06	6.8e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—VEGFA—hematologic cancer	4.98e-06	6.77e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—TXN—hematologic cancer	4.97e-06	6.75e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.97e-06	6.75e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.97e-06	6.75e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTP1—hematologic cancer	4.95e-06	6.72e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—NRAS—hematologic cancer	4.92e-06	6.68e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HRAS—hematologic cancer	4.92e-06	6.68e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.87e-06	6.61e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CD44—hematologic cancer	4.86e-06	6.6e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NQO1—hematologic cancer	4.86e-06	6.6e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.79e-06	6.5e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—MTHFR—hematologic cancer	4.78e-06	6.49e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.76e-06	6.46e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—MAPK3—hematologic cancer	4.71e-06	6.4e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL6—hematologic cancer	4.71e-06	6.39e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ABCB1—hematologic cancer	4.69e-06	6.36e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.67e-06	6.35e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYCS—hematologic cancer	4.6e-06	6.24e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TGFB1—hematologic cancer	4.57e-06	6.21e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	4.57e-06	6.2e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTM1—hematologic cancer	4.55e-06	6.18e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NCOR1—hematologic cancer	4.55e-06	6.18e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SLC22A1—hematologic cancer	4.55e-06	6.18e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CRABP1—hematologic cancer	4.55e-06	6.18e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.51e-06	6.12e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTP1—hematologic cancer	4.44e-06	6.03e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.43e-06	6.02e-05	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKT1—hematologic cancer	4.34e-06	5.9e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.3e-06	5.84e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NUP98—hematologic cancer	4.29e-06	5.83e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—KRAS—hematologic cancer	4.24e-06	5.75e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ABCB1—hematologic cancer	4.21e-06	5.71e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.17e-06	5.66e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.17e-06	5.66e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NUP214—hematologic cancer	4.14e-06	5.62e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.11e-06	5.58e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.08e-06	5.55e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.08e-06	5.55e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.05e-06	5.5e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—MTR—hematologic cancer	4.05e-06	5.5e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTP1—hematologic cancer	4.05e-06	5.5e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—MTHFR—hematologic cancer	4.02e-06	5.46e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CG—hematologic cancer	4.01e-06	5.45e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ENO2—hematologic cancer	3.97e-06	5.4e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.92e-06	5.32e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CA—hematologic cancer	3.89e-06	5.28e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.85e-06	5.24e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ABCB1—hematologic cancer	3.84e-06	5.21e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SDC1—hematologic cancer	3.77e-06	5.12e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TP53—hematologic cancer	3.76e-06	5.11e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTM1—hematologic cancer	3.72e-06	5.06e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NCOR1—hematologic cancer	3.72e-06	5.06e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CREBBP—hematologic cancer	3.72e-06	5.05e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—MTHFR—hematologic cancer	3.61e-06	4.9e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—HRAS—hematologic cancer	3.6e-06	4.89e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.54e-06	4.81e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CD—hematologic cancer	3.53e-06	4.79e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—ALB—hematologic cancer	3.48e-06	4.73e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CG—hematologic cancer	3.38e-06	4.59e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3R1—hematologic cancer	3.33e-06	4.52e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—MTHFR—hematologic cancer	3.29e-06	4.47e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NQO1—hematologic cancer	3.2e-06	4.35e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CD44—hematologic cancer	3.2e-06	4.35e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.18e-06	4.32e-05	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—AKT1—hematologic cancer	3.18e-06	4.32e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CREBBP—hematologic cancer	3.13e-06	4.25e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CB—hematologic cancer	3.07e-06	4.18e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.03e-06	4.12e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CYCS—hematologic cancer	3.03e-06	4.12e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.01e-06	4.09e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CD—hematologic cancer	2.97e-06	4.03e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.9e-06	3.94e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.81e-06	3.82e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3R1—hematologic cancer	2.8e-06	3.81e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.76e-06	3.75e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.67e-06	3.63e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.67e-06	3.62e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTEN—hematologic cancer	2.66e-06	3.61e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ALB—hematologic cancer	2.63e-06	3.57e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CB—hematologic cancer	2.59e-06	3.51e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CREBBP—hematologic cancer	2.56e-06	3.48e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—EP300—hematologic cancer	2.53e-06	3.44e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.53e-06	3.44e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3R1—hematologic cancer	2.52e-06	3.42e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.46e-06	3.33e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.46e-06	3.33e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CD—hematologic cancer	2.43e-06	3.3e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ALB—hematologic cancer	2.4e-06	3.26e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.32e-06	3.16e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.29e-06	3.12e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTEN—hematologic cancer	2.24e-06	3.04e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.17e-06	2.95e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—EP300—hematologic cancer	2.13e-06	2.9e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.12e-06	2.88e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTEN—hematologic cancer	2.01e-06	2.73e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—EP300—hematologic cancer	1.91e-06	2.6e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.87e-06	2.55e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTEN—hematologic cancer	1.83e-06	2.49e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.82e-06	2.48e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—EP300—hematologic cancer	1.75e-06	2.37e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.69e-06	2.3e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.6e-06	2.18e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ALB—hematologic cancer	1.58e-06	2.15e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CA—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKT1—hematologic cancer	1.53e-06	2.08e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.51e-06	2.06e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.42e-06	1.92e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.4e-06	1.9e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.29e-06	1.75e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKT1—hematologic cancer	1.29e-06	1.75e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTEN—hematologic cancer	1.21e-06	1.64e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKT1—hematologic cancer	1.16e-06	1.57e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—EP300—hematologic cancer	1.15e-06	1.56e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKT1—hematologic cancer	1.05e-06	1.43e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CA—hematologic cancer	8.52e-07	1.16e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKT1—hematologic cancer	6.96e-07	9.45e-06	CbGpPWpGaD
